Oncology Certified Nurse (OCN) Test 2026 – 400 Free Practice Questions to Pass the Exam

The use of Etoposide, Cisplatin, and Carboplatin in the treatment of small cell lung cancer (SCLC) is grounded in the established efficacy of these chemotherapeutic agents against this aggressive type of lung cancer. SCLC is known for its rapid growth and early metastasis, making effective treatment vital.

Etoposide is a topoisomerase II inhibitor, which disrupts DNA synthesis and function, thereby hindering cancer cell proliferation. It's a cornerstone in the standard chemotherapeutic regimens for SCLC, often used in combination with other agents to improve outcomes.

Cisplatin and Carboplatin are both platinum-based agents that work by forming DNA cross-links, which ultimately leads to apoptosis in cancer cells. Their inclusion in the treatment regimen is due to their potent activity against SCLC, making them crucial in combination therapies that target this type of lung cancer.

Together, these agents are known to induce a significant response in many patients, improving survival rates and increasing the chances of a positive treatment outcome. This combination therapy is favored in clinical practice for management of SCLC due to their synergistic effects.

In contrast, other options either include agents that are not typically used in SCLC treatment or do not encompass the